Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study

Key Points

• Early response significantly improved in patients receiving anifrolumab treatment, suggesting effective management of systemic lupus erythematosus.
• The interim analysis included diverse patient profiles across multiple centers, demonstrating varied responses to the intervention.
• Observational analysis examines outcomes across ongoing multicentre participation, enhancing data relevance for lupus treatment.
• These findings highlight the potential of anifrolumab, calling for further validation in larger populations and longer follow-ups.